Therapeutics and Prophylaxis - HAN
Breadcrumb
Jump To:
New COIVD-19 Therapeutics Announcements
- May 25, 2023: FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults
- May 9, 2023: HHS Secretary Signs 11th Amendment to PREP Act for COVID-19 Medical Countermeasures
- Apr. 18, 2023: HHS Announces ‘HHS Bridge Access Program For COVID-19 Vaccines and Treatments’ to Maintain Access to COVID-19 Care for the Uninsured
- Feb. 24, 2023: IDPH announces statewide COVID-19 Test to TReat Telemedicine Program
Overview of COVID-19 Therapeutics and Prophylaxis for Non-Hospitalized Patients
The resources below provide:
- Interim guidance on outpatient treatment decisions for patients at risk of developing severe COVID-19.
- Comparison table of treatment options.
- How providers may obtain these treatments or prophylaxis for their patients.
- Where providers can refer their patients for infusion therapies.
- Reporting requirements.


Treatment
*Adapted from COCA call 1/22/22
Clinicians should refer to the EUA healthcare provider fact sheets for further details on Paxlovid, remdesivir, and molnupiravir. For the FDA-approved remdesivir (Veklury) for 12 yrs and older weight at least 40kg, refer to the full prescribing information.
Clinicians should refer to the EUA healthcare provider fact sheets for further details on Paxlovid, remdesivir, and molnupiravir. For the FDA-approved remdesivir (Veklury) for 12 yrs and older weight at least 40kg, refer to the full prescribing information.
Prophylaxis
IMPORTANT UPDATE 1/26/2023: Evusheld is not currently authorized by the FDA for emergency use in the U.S.
Description |
|
Patient Profiles |
|
Become a Provider
HHS currently distributes an allocation of Paxlovid and Molnupiravir to each state. All medications must be ordered through the Health Partners Order Portal (HPOP).
- Sign up with HPOP here.
- If you need help getting set up, email DPH.MABTherapy@illinois.gov
Locate Therapeutics and Prophylaxis In The City
- Infusion Providers Accepting External Referrals:
AMITA Health Saints Mary and Elizabeth Medical Center | Tel: 312-770-8534 Fax: 312-770-3182 |
John H Stroger Jr Hospital of Cook County | covidtherapeutics@cookcountyhhs.org |
Provident Hospital of Chicago | covidtherapeutics@cookcountyhhs.org |
Saint Anthony Hospital | ttruesdell@sahchicago.org |
Swedish Covenant Hospital | Tel: 773-907-7700 |
- Test to Treat in Chicago
- Providers who don’t want to receive allocations can use the ASPR COVID-19 Therapeutics Locator to find providers, pharmacies and infusion centers with doses on hand.
- For providers looking for immediate access to COVID-19 Therapeutics, available doses may be found on the IDPH Matchmaker Site. If you are a provider and have extra doses in between distribution cycles, please use this site so others have access.
State and Federal Reporting Requirements
Reporting into Health Partner Ordering Portal (HPOP)
Reporting into HHS Teletracking - All therapeutics that require reporting into this portal are currently paused.
- Report utilization and doses on hand of Paxlovid and Legevrio twice per week by 11:59pm every Monday and Thursday. Report on hand doses of all other therapeutics once per week by 11:59 every Thursday.
- When reporting utilization of each product, report the quantity used since the last report. Do not report the cumulative amount over time.
- For any issues related to ordering or reporting of HPOP therapeutics, reach out to cars_helpdesk@cdc.gov or 833-748-1979
- Click here (https://aspr.hhs.gov/COVID-19/Therapeutics/Distribution/Pages/process-for-ordering.aspx) for more information on HPOP reporting.
Reporting into HHS Teletracking - All therapeutics that require reporting into this portal are currently paused.
- Instructions for Completion (https://www.cdc.gov/nhsn/pdfs/covid19/ltcf/57.158-toi-508.pdf)

Provider Resource Library and Other Useful Links
- Webinars
- Research
- MMWR: Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages
- MMWR: Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities and Healthcare Systems
- CDC MMWR: Hospitalization and ED Encounters for COVID-19 After Paxlovid Treatment
- MMWR: Equitable Dispensing of COVID-19 Oral Antivirals
- MMWR: Racial and Ethnic Disparities in Outpatient Treatment of COVID-19
- MMWR: Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years
- Educational Tools
- Side-by-Side Overview of COVID-19 Therapeutics Authorized or Approved
- NIH COVID-19 Treatment Guidelines
- COVID-19 Treatment Guidelines and Considerations for the Immunocompromised
- Clinical Considerations for COVID-19 Treatment in Outpatients
- ASPR Paxlovid Info Sheet
- Paxlovid Drug interactions
- FDA Updated Paxlovid Fact Sheet
- NIH Paxlovid Checklist Tool for Prescribers
- FDA Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers
- FDA Updated Lagevrio Fact Sheet
- Lagevrio Information Sheet
- Veklury (remdesivir) Prescribing Information
- COVID-19 Drug Interactions Checker App
- Underlying Medical Conditions Associated With Higher Risk for Severe Covid-19
- Printable Posters
- Other Links
- Fact Sheet: COVID-19 Public Health Emergency Transition Roadmap
- IDPH Covid-19 Therapeutics Consumer Experience Survey
- HHS Secretary Becerra renewed the COVID-19 Public Health Emergency Declaration for 90 days (7/15/2022)
- FDA Authorizes Pharmacists to Prescribe Paxlovid
- Bebtelovimab and Evushed EUA retain neutralization against all circulating variants
Shelf life Extensions
Shelf-Life Extension infomation. Click the links to view the affected lot numbers.
New! Searchable database of COVID-19 Therapeutic Product Expiration Dates is now available
New! Searchable database of COVID-19 Therapeutic Product Expiration Dates is now available
- Evusheld
- Paxlovid
- Lagevrio
- Bebtelovimab
- Sotrovimab
- Guidelines for Product Return: Bamlanivimab, BAM/ETE, REGEN-COV, Sotrovimab